Editing 2955

&nbsp;<br/>T7AG<br/>TAATACGACTCACTATAAGG<br/>5'UTR<br/>tcttctggtccccacagactcagagagaacc

Nde1 (cloning site 1)<br/>CATATG<br/>TAAGGCGC<br/>5'UTR<br/>GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGACCCCGG&nbsp;<br/>Kozak NcoI<br/>GCCACCATGG



Stop<br/>TGATAATAG<br/>GCCGGCcgg&nbsp;<br/>3'UTR AES-mtRNR1<br/>&nbsp; &nbsp;Pan troglodytes amino-terminal enhancer of split (AES) 3'UTR<br/>&nbsp; &nbsp;CTGGTACTGCATGCACGCAATGCTAGCTGCCCCTTTCCCGTCCTGGGTACCCCGAGTCTCCCCCGACCTCG GGTCCCAGGTATGCTCCCACCTCCACCTGCCCCACTCACCACCTCTGCTAGTTCCAGACACCTCC&nbsp;<br/>&nbsp; &nbsp;human mitochondrial encoded 12S ribosomal RNA 3'UTR<br/>&nbsp; &nbsp;CAAGCACGCAGCAATGCAGCTCAAAACGCTTAGCCTAGCCACACCCCCACGGGAAACAGCAGTGATTAAC CTTTAGCAATAAACGAAAGTTTAACTAAGCTATACTAACCCCAGGGTTGGTCAATTTCGTGCCAGCCACACC&nbsp;

<br/>Not1 (cloning site 2)<br/>GCGGCCGC<br/>polyA<br/>CCGCGGCCGCAAGCTGCTTACATAGAACTCGCGGCGATTGGCATGCCGCCTTAAAATTTTTATTTTATTTTTtCTTTTCTTTTCCGAATCGGATTTTGTTTTTAATATTTCAAAAAAAAAAAAAAAAAAAAAAAAACGCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAttaatAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAttaatAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAttaattaatctagaacgcgTCGAGGGGAATTAATTCTTGAAGACGAAAGGGCCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGAGCTC



<br/>Modified 5’-cap0 structure using ARCA (Anti Reverse Cap Analog) or 5'-cap1 structure using CleanCap<br/>5´-untranslated region&nbsp;<br/>3’-UTR: comprises two sequence elements derived from the amino-terminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA to confer RNA stability and high total protein expression.

N1-methyl pseudouridine is (1mt).

&nbsp; &nbsp; &nbsp;(1) an ionizable or cationic lipid [e.g., SM-102 (mRNA-1273) and ALC-0315 (BNT162b2)], bearing tertiary or quaternary amines to encapsulate the polyanionic mRNA; (2) a helper lipid [LNPs of Moderna and BioNTech contain the same helper lipid 1,2-distearoyl-snglycero-3-phosphocholine (DSPC)] that resembles the lipids in the cell membrane; (3) cholesterol to stabilize the lipid bilayer of the LNP; and (4) a polyethylene glycol (PEG)-lipid [(2-[(polyethylene glycol)− 2000]-N,N-ditetradecylacetamide (PEG2000-DMA) in BNT162b2 or 1,2-dimyristoyl-rac-glycero3-methoxypolyethylene glycol-2000 (PEG2000-DMG) in mRNA-1273] to lend the nanoparticle a hydrating layer, improve colloidal stability, and reduce protein absorption.

&nbsp; &nbsp; &nbsp; anti-reverse-Cap-analog [CAP-0 (N7MeGpppN) structure] or Clean Cap [CAP-1 (N7MeGpppN2′-OMe)&nbsp;

<br/>vaccinia virus immune evasion proteins E3, K3, and B18R (EKB).14,&nbsp; 15,&nbsp; 16 The latter set of genes counteracts type I interferon-dependent cellular defense mechanisms activated by mRNA delivery, which inhibit mRNA translation and may compromise cell viability upon repetitive transfection.17,&nbsp; 18 Transfecting these two classes of factors along with double-stranded reprogramming-enhancing microRNAs (miRNAs) from the 302/367 cluster19,&nbsp; 20 on 4 consecutive days has been shown to improve the efficiency and speed of generating stable iPSC lines from human neonatal and adult fibroblasts
[[Category:Cloning]]